Medical Cannabis and Psychosis Risk: Policy Brief for Regulators

Medical cannabis provides clinically meaningful benefit for eligible patients when used under appropriate clinical supervision. Psychosis risk is real but concentrated in specific high-risk groups and use patterns. Any federal or state policy should strengthen safeguards within medical programs rather than restrict legitimate therapeutic access.

Core Principles

• Preserve access to medical cannabis for patients when benefits outweigh risks, as determined by a qualified clinician 
• Systematically identify and manage elevated-risk patients through structured assessment and routine, frequent follow-up appointments 
• Ensure products, labeling, and program rules support safe clinical use 
• Maintain clear legal and regulatory programs to facilitate supervised medical prescription and discourage self-medication through non-therapeutic retail channels 

Evidence Context

• Longitudinal studies show association between cannabis use and increased psychosis risk, particularly with early onset, frequent use, and high-THC products 
• Twin studies, on the other hand, indicate no or minimal increased risk  
• Risk is multifactorial and concentrated: adolescents, personal/family history of psychosis, high-potency daily use 
• Most medical patients do not develop psychosis; risk management allows safe therapeutic use 

Given that the risk is multifactorial, specific to identifiable groups, and the absolute risk is very low, policy should not address this risk broadly, but only in the context of those specific groups.  

Recommended Safeguards for Medical Programs

Clinical Assessment Requirements

• Require certifying clinicians to document: treating condition, prior treatments, cannabis history, personal and family history of psychosis, substance use, age, and psychiatric comorbidity 
• Establish clear contraindications: 
  • Absolute: Active psychosis, unstable psychotic disorder 
  • Relative: Age under 25, strong family history of psychosis/schizophrenia, prior cannabis-induced psychosis, serious mental illness 
• Mandate periodic clinical follow-up (minimum annually; more frequently for high-risk patients) including mental status assessment 

Product Standards and Formulation

• Maintain rigorous quality control, accurate labeling, and batch testing across all medical products 
• Encourage availability of lower-THC formulations to expand safe options for psychiatrically vulnerable patients 
• Ensure medical dispensaries stock products appropriate for supervised therapeutic use, not just high-potency recreational products 

Labeling and Patient Education

• Require balanced, evidence-based warnings on medical product labels: 
  • State increased psychosis risk in patients with personal/family history of psychosis or serious mental illness 
  • Note higher risk with high-THC, frequent use, especially in young adults 
  • Explicitly differentiate supervised medical use from unsupervised recreational use 
• Provide clinician guidance on initiating, titrating, and monitoring cannabis in patients with psychiatric conditions 
• To the extent possible under law, move to a prescription model where clinicians must specify what product to get and how to use it 
• Supply patient handouts explaining expected benefits, common side effects, early warning signs of psychosis, and when to seek urgent care 

System Oversight and Pharmacovigilance

• Provide patient-specific sales information to clinicians through an online portal so that they can see what their patients are buying in order to provide guidance and corrective intervention if needed
• Collect de-identified data on serious psychiatric adverse events, including psychosis, within medical programs 
• Review trends regularly to refine contraindication lists, educational materials, and product standards 
• Use findings to improve safety without defaulting to broad access restrictions 
• Maintain and enforce strict prohibitions against medical claims by manufacturers and dispensaries in both medical and recreational markets. For examples:  
  • Products and dispensaries must not imply medical benefits by use of “may” or “might” in messaging 
  • Products must not imply medical benefits by use of product names that imply a result like “sleep” or “calm” 
  • Sales agents must not imply medical benefits by use of indirect association like “patients like you tell us that this product does X, Y, or Z” 

Implementation Priorities

1. Mandate provider education that encompasses dosing, risk assessment, and risk mitigation 
2. Change certification/recommendations into formal, binding prescriptions to require clinicians to be responsible for their advice and point-of-sale to comply without upselling 
3. Create online portal like Prescription Drug Monitoring Programs (PDMP) to inform clinicians of what their patients actual purchase and how much 
4. Establish adverse-event reporting pathways linked to product and patient registries 
5. Coordinate messaging across health departments, medical boards, and dispensaries to ensure consistency 

Psychosis risk does not justify restricting medical cannabis programs. Instead, it calls for structured risk assessment, targeted warnings, product diversity, clinical monitoring, and ongoing data review. These safeguards allow legitimate therapeutic use while protecting vulnerable populations. =